The U.S. demand for drug delivery products is projected to reach $251 billion in 2019, according to the Freedonia Group, a leading international business research company. Oral dosage formulations will remain the largest-selling group of drug delivery products over the long term, but patent expirations and competition from generic brands will soften the growth potential of this product segment overall. Drawing on key findings from Freedonia's recent study Drug Delivery Products, here’s a look at the market outlook for oral medications, including controlled-release formulations and niche applications.